The immunomodulatory role of PDEs inhibitors in immune cells: therapeutic implication in rheumatoid arthritis. (November 2020)

• Record Type: Journal Article
• Authors: He, YuFei; Huang, Yadan; Mai, ChuTian; Pan, Hudan; Luo, Hai-Bin; Liu, Liang; Xie, Ying
• Is Part Of: Pharmacological research. Volume 161(2020)
• Publication Date: 2020-11
• Subjects: PDEs inhibitors -- rheumatoid arthritis -- immune cells -- second messengers -- anti-inflammatory -- immunomodulatory; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Research -- Periodicals; Médicaments -- Recherche -- Périodiques; Pharmacologie -- Périodiques; 615.105
• DOI: 10.1016/j.phrs.2020.105134
• Languages: English
• ISSNs: 1043-6618

Abstract

Graphical abstract: Abstract: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by inflammatory synovitis and progressive joint. Although the etiology is extremely complex, overwhelming evidence suggests that dysregulation or imbalance of the immune system plays a central role in disease pathogenesis. The bone loss and joint destruction are immunological insults mediated by infiltration and abnormal activation of various immune cells. Since pharmacological inhibition of cyclic nucleotide phosphodiesterases (PDEs), which degrade cyclic AMP and cyclic GMP, can regulate the activity of multiple immune cells, which are considered as a potential strategy for treating RA. Therefore, this review attempted to summarize the modulating effects of PDEs on immune cells and described the molecular underpinnings and potential clinical application of PDEs inhibitors for RA.